Tobira Therapeutics (TBRA) Reports Q3 Loss of $1.22/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Tobira Therapeutics Reports Third Quarter 2015 Financial Results
November 10, 2015 4:02 PM ESTSOUTH SAN FRANCISCO, Calif., Nov. 10, 2015 /PRNewswire/ --Â Tobira Therapeutics, Inc. (NASDAQ: TBRA), a biopharmaceutical company developing novel treatments for non-alcoholic steatohepatitis (NASH) and other serious immuno-inflammatory and fibrotic diseases, today reported business highlights and financial results for the third quarter of 2015.
"We are making excellent progress on CENTAUR, our Phase 2b study of cenicriviroc for the treatment of NASH and liver fibrosis. CENTAUR is a well-powered large Phase 2b NASH study that has completed enrollment and exclusively enrolled patients at greater risk of progression to cirrhosis. The study... More
